Statin and clinical outcomes of primary prevention in individuals aged >75 years: The SCOPE-75 study
Atherosclerosis Mar 09, 2019
Kim K, et al. - In this retrospective, propensity score-matched study, researchers investigated whether cardiovascular risk and all-cause death in individuals aged >75 years were attenuated effectively by using statin for primary prevention. Participants were 1559 statin-naïve patients without a history of atherosclerotic cardiovascular disease before the index visit. The final analysis was performed in 1278 patients (639 statin users, 639 statin non-users) following propensity score matching, with a focus on major adverse cardiovascular and cerebrovascular events (MACCE; including cardiovascular death, nonfatal myocardial infarction, coronary revascularization, and nonfatal stroke or transient ischemic attack) and all-cause death. In individuals aged >75 years, an attenuated risk of cardiovascular events and all-cause death was observed in association with statin therapy for primary prevention. Based on these findings, it was considered beneficial to ensure more active statin use in this population.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries